{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T21:02:57Z","timestamp":1785358977382,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ijgc.2026.104733","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:42:57Z","timestamp":1777131777000},"page":"104733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence and clinical features of cataracts: an under-recognized adverse event with mirvetuximab soravtansine-gynx in ovarian cancer"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2221-7441","authenticated-orcid":false,"given":"Matthew L.","family":"Flint","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6940-6957","authenticated-orcid":false,"given":"Anna","family":"Shvygin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9264-8327","authenticated-orcid":false,"given":"Paul","family":"Johannet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4247-8008","authenticated-orcid":false,"given":"Seth","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Konner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Tew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel N.","family":"Grisham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine H.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6548-6879","authenticated-orcid":false,"given":"Julia","family":"Canestraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8217-4554","authenticated-orcid":false,"given":"Roisin E.","family":"O\u2019Cearbhaill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ijgc.2026.104733_bib1","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrc4019","article-title":"Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian cancer","volume":"15","author":"Bowtell","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"27","key":"10.1016\/j.ijgc.2026.104733_bib2","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.19.00194","article-title":"Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives","volume":"37","author":"Pujade-Lauraine","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104733_bib3","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The journey of antibody-drug conjugates: lessons learned from 40 years of development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104733_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/cac2.12517","article-title":"Development of antibody-drug conjugates in cancer: overview and prospects","volume":"44","author":"Ruan","year":"2024","journal-title":"Cancer Commun (Lond)"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104733_bib5","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1038\/bjc.2014.567","article-title":"Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis Consortium study","volume":"111","author":"K\u00f6bel","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijgc.2026.104733_bib6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ygyno.2024.09.021","article-title":"Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma","volume":"191","author":"Rushton","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104733_bib7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ygyno.2024.06.003","article-title":"Ocular side effects of anticancer agents used in the treatment of gynecologic cancers","volume":"188","author":"Crowley","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104733_bib8","article-title":"Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine","volume":"47","author":"Hendershot","year":"2023","journal-title":"Gynecol Oncol Rep"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104733_bib9","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/ICU.0000000000001063","article-title":"Ocular toxicities associated with antibody drug conjugates","volume":"35","author":"Marshall","year":"2024","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.ijgc.2026.104733_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104230","article-title":"Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with FRa positive expression: a systematic review and meta-analysis","volume":"194","author":"Wang","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104733_bib11","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.ijgc.2026.104733_bib12","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ijgc.2026.104733_bib13","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FRalpha-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.ijgc.2026.104733_bib14","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/archopht.122.4.487","article-title":"Prevalence of cataract and pseudophakia\/aphakia among adults in the United States","volume":"122","author":"Congdon","year":"2004","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104733_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.19366","article-title":"Cataract development among pediatric patients with uveitis","volume":"7","author":"Hsu","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijgc.2026.104733_bib16","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.2147\/OPTH.S537700","article-title":"Cataract induced by glucocorticoids","volume":"19","author":"Jian","year":"2025","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104733_bib17","article-title":"Pharmacovigilance of drug-induced cataract using the FDA Adverse Event Reporting System","volume":"15","author":"Hong","year":"2025","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104733_bib18","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/archopht.1993.01090060119035","article-title":"The Lens Opacities Classification System III. The Longitudinal Study of Cataract study group","volume":"111","author":"Chylack","year":"1993","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104733_bib19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/09286586.2012.759598","article-title":"Ten-year incidence rates of age-related cataract in the Age-Related Eye Disease Study (AREDS): AREDS report no. 33","volume":"20","author":"Koo","year":"2013","journal-title":"Ophthal Epidemiol"},{"key":"10.1016\/j.ijgc.2026.104733_bib20","doi-asserted-by":"crossref","first-page":"11847","DOI":"10.2147\/IJN.S490400","article-title":"Unveiling the hidden risks: an update decade-long analysis of Abraxane-related adverse events from the FAERS database","volume":"19","author":"Zhao","year":"2024","journal-title":"Int J Nanomedicine"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104733_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105573","article-title":"Toxicity and efficacy of antibody-drug conjugates in advanced solid tumors: a retrospective single-center analysis of clinical trials","volume":"10","author":"Woodford","year":"2025","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104733_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s40360-025-00965-5","article-title":"Drug-induced sinusoidal obstruction syndrome: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System (FEARS)","volume":"26","author":"Sun","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104733_bib23","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V99.7.2310","article-title":"Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy","volume":"99","author":"Rajvanshi","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104733_bib24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11523-024-01058-9","article-title":"Emerging toxicities of antibody-drug conjugates for breast cancer: clinical prioritization of adverse events from the FDA Adverse Event Reporting System","volume":"19","author":"Cecco","year":"2024","journal-title":"Target Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104733_bib25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jamaoncol.2025.5763","article-title":"Ocular toxic effects during mirvetuximab soravtansine therapy","volume":"12","author":"Haidar","year":"2026","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104733_bib26","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (InnovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104733_bib27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104733_bib28","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/0039-6257(86)90077-9","article-title":"Corticosteroid-induced cataracts","volume":"31","author":"Urban","year":"1986","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104733_bib29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12951-025-03277-2","article-title":"Current progress and remaining challenges of peptide-drug conjugates (PDCs): next generation of antibody-drug conjugates (ADCs)?","volume":"23","author":"Wang","year":"2025","journal-title":"J Nanobiotechnology"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26002641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26002641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T20:22:33Z","timestamp":1785356553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26002641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1048891X26002641"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104733","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence and clinical features of cataracts: an under-recognized adverse event with mirvetuximab soravtansine-gynx in ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104733","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104733"}}